PROGRAM SNAPSHOT

Seraxis — SR-02

🔬 Emerging Contender Regulatory Filing

Cleared to start human trials — dosing and enrollment status aren't confirmed in the sources we've reviewed.

What's actually shown: FDA IND allowance granted for a clinical study of SR-02 replacement islets. Current dosing and enrollment status have not been independently re-verified — confirm before relying on this page for enrollment specifics.
Last verified: 2026-08-24. Sources: Seraxis press release.

This is a Program Snapshot, not yet a full Trial Report Card — a full Report Card means the deeper eligibility, risk, and enrollment research we do for each Cure Radar post. Follow @t1dcureintelligence for the full breakdown when this program gets its own deep-dive.

← Back to the full leaderboard